SamanTree Medical Secures €20M EIB Boost for Real-Time Cancer Imaging
January 31, 2026, 3:56 pm
SamanTree Medical secured €20 million from the EIB, bolstering its innovative Histolog Scanner. This device delivers rapid, high-resolution imaging of tissue during surgery. It helps surgeons detect remaining abnormal cells instantly. This capability reduces reoperation rates significantly, particularly in breast cancer and prostatectomy cases. The funding accelerates global commercial expansion and critical R&D, marking a pivotal step for precision oncology and improved patient outcomes worldwide.
A new era in cancer surgery dawns. SamanTree Medical, a Belgian MedTech innovator, secured significant investment. The European Investment Bank (EIB) provided €20 million. This capital propels the company's groundbreaking Histolog Scanner. The funding aims to revolutionize real-time surgical imaging. It promises faster, more precise cancer detection during operations.
The Histolog Scanner is a game-changer. It employs advanced confocal microscopy. This technology visualizes tissue microstructure instantly. Surgeons gain unprecedented intraoperative insight. They can assess excised tissue within minutes. This immediate feedback is crucial for patient outcomes.
Traditional pathology workflows take time. Surgeons often wait for lab results. The Histolog Scanner eliminates this delay. It provides histology-like images directly in the operating room. This allows immediate decision-making. Patients remain on the operating table. This reduces surgical complications and patient anxiety.
The scanner's speed is remarkable. It captures nearly 30,000 images simultaneously. This contrasts sharply with sequential imaging methods. High-resolution images appear in approximately one minute. Crucially, the process does not damage the tissue specimen. This preserves samples for further conventional analysis if needed.
Clinical results prove the Histolog Scanner's impact. It has been used in over 6,000 patients. The device shows compelling results across multiple tissue types. Oncologic surgery stands to benefit profoundly.
Breast-conserving surgery is a prime example. The SHIELD study revealed significant improvements. When physicians used Histolog images, reoperation rates dropped. They fell from 30% to a mere 10%. This represents a powerful 67% reduction. Lower reoperation rates mean better patient experiences. They also signify reduced healthcare costs.
The Histolog Scanner also excels in prostatectomies. Research compares it to frozen-section analysis. Frozen section is the current gold standard. Histolog produced similar results. Yet, it offered substantial time savings. Imaging and interpretation with Histolog take 5-20 minutes. Frozen section analysis typically requires 45-60 minutes. Time is a critical factor in surgery. Faster diagnostics improve surgical efficiency.
The scanner boasts high accuracy. Studies show impressive sensitivity. It ranges from 73% to 91%. Specificity is equally strong, ranging from 91% to 100%. These figures compare favorably to conventional pathology. Surgeons can trust the intraoperative assessments.
Beyond cancer detection, the technology supports enhanced surgical techniques. Intraoperative assessment allows for nerve-sparing surgeries. This is particularly vital in radical prostatectomy. Such procedures can significantly reduce side effects. Erectile dysfunction, a common complication, may be mitigated. This improves quality of life for cancer survivors.
The €20 million EIB financing is a strategic move. It is backed by InvestEU. InvestEU is the EU’s flagship investment program. The EIB supports highly innovative companies. Venture debt is a key instrument for growth acceleration. This funding ensures leading medical technology companies thrive in Europe.
This investment underscores the EIB's commitment. It reflects a long-standing dedication to medical innovation. Supporting advanced healthcare technologies is central to its mission. It drives positive impact for patients and healthcare systems across Europe and beyond.
SamanTree Medical's funding stands out. The European MedTech landscape saw various investments in 2025. Other companies secured capital for imaging and diagnostic innovation. PIUR IMAGING raised €5.6 million for 3D ultrasound. Juisci secured €5.5 million for an AI platform. M2care raised €26 million for its venture studio model. SamanTree's larger ticket size is notable. Its focus on capital-intensive hardware innovation is also distinctive. Institutional support for such critical medical devices remains strong.
The financing fuels further development. It supports ongoing research activities. SamanTree will advance its Histolog Scanner. It will also expand its commercial footprint. The company targets growth across Europe. Expansion into the United States market is also planned.
SamanTree Medical, founded in 2014, holds a clear mission. It aims to improve oncologic surgery. Innovative imaging solutions are the core. This EIB investment strengthens that commitment. It accelerates the delivery of cutting-edge technology to patients. It solidifies SamanTree's position as a leader in precision oncology. This represents a significant leap forward in the fight against cancer.
A new era in cancer surgery dawns. SamanTree Medical, a Belgian MedTech innovator, secured significant investment. The European Investment Bank (EIB) provided €20 million. This capital propels the company's groundbreaking Histolog Scanner. The funding aims to revolutionize real-time surgical imaging. It promises faster, more precise cancer detection during operations.
The Histolog Scanner is a game-changer. It employs advanced confocal microscopy. This technology visualizes tissue microstructure instantly. Surgeons gain unprecedented intraoperative insight. They can assess excised tissue within minutes. This immediate feedback is crucial for patient outcomes.
Traditional pathology workflows take time. Surgeons often wait for lab results. The Histolog Scanner eliminates this delay. It provides histology-like images directly in the operating room. This allows immediate decision-making. Patients remain on the operating table. This reduces surgical complications and patient anxiety.
The scanner's speed is remarkable. It captures nearly 30,000 images simultaneously. This contrasts sharply with sequential imaging methods. High-resolution images appear in approximately one minute. Crucially, the process does not damage the tissue specimen. This preserves samples for further conventional analysis if needed.
Clinical results prove the Histolog Scanner's impact. It has been used in over 6,000 patients. The device shows compelling results across multiple tissue types. Oncologic surgery stands to benefit profoundly.
Breast-conserving surgery is a prime example. The SHIELD study revealed significant improvements. When physicians used Histolog images, reoperation rates dropped. They fell from 30% to a mere 10%. This represents a powerful 67% reduction. Lower reoperation rates mean better patient experiences. They also signify reduced healthcare costs.
The Histolog Scanner also excels in prostatectomies. Research compares it to frozen-section analysis. Frozen section is the current gold standard. Histolog produced similar results. Yet, it offered substantial time savings. Imaging and interpretation with Histolog take 5-20 minutes. Frozen section analysis typically requires 45-60 minutes. Time is a critical factor in surgery. Faster diagnostics improve surgical efficiency.
The scanner boasts high accuracy. Studies show impressive sensitivity. It ranges from 73% to 91%. Specificity is equally strong, ranging from 91% to 100%. These figures compare favorably to conventional pathology. Surgeons can trust the intraoperative assessments.
Beyond cancer detection, the technology supports enhanced surgical techniques. Intraoperative assessment allows for nerve-sparing surgeries. This is particularly vital in radical prostatectomy. Such procedures can significantly reduce side effects. Erectile dysfunction, a common complication, may be mitigated. This improves quality of life for cancer survivors.
The €20 million EIB financing is a strategic move. It is backed by InvestEU. InvestEU is the EU’s flagship investment program. The EIB supports highly innovative companies. Venture debt is a key instrument for growth acceleration. This funding ensures leading medical technology companies thrive in Europe.
This investment underscores the EIB's commitment. It reflects a long-standing dedication to medical innovation. Supporting advanced healthcare technologies is central to its mission. It drives positive impact for patients and healthcare systems across Europe and beyond.
SamanTree Medical's funding stands out. The European MedTech landscape saw various investments in 2025. Other companies secured capital for imaging and diagnostic innovation. PIUR IMAGING raised €5.6 million for 3D ultrasound. Juisci secured €5.5 million for an AI platform. M2care raised €26 million for its venture studio model. SamanTree's larger ticket size is notable. Its focus on capital-intensive hardware innovation is also distinctive. Institutional support for such critical medical devices remains strong.
The financing fuels further development. It supports ongoing research activities. SamanTree will advance its Histolog Scanner. It will also expand its commercial footprint. The company targets growth across Europe. Expansion into the United States market is also planned.
SamanTree Medical, founded in 2014, holds a clear mission. It aims to improve oncologic surgery. Innovative imaging solutions are the core. This EIB investment strengthens that commitment. It accelerates the delivery of cutting-edge technology to patients. It solidifies SamanTree's position as a leader in precision oncology. This represents a significant leap forward in the fight against cancer.